Expands in personal flow cytometer segment
July 11, 2011 | Monday | News
RANK 4
Revenue  207 crore*
|
| Becton Dickinson |
| Director, BD Biosciences: Mr Sunit
Trivedi |
| Business: Supplier of
diagnostic bioresearch and medical equipment |
Start-up Year: 1994
|
Address: 6th Floor, Signature
Towers, B South City 1,
Gurgaon-122001, Haryana
Tel: +91-124-2383566
Fax: +91-124-2383224
Website: www.bd.com/india |
With the takeover of Accuri, which has
a range of compact and affordable products, the
company is looking at significant growth in 2011
Becton Dickinson (BD) is a US-based company
that manufactures and sells a broad range of medical supplies, devices,
laboratory equipments and diagnostic products. BD operates in India
through a wholly-owned subsidiary, BD India.
BD Biosciences, a division of BD India is focused on improving drug
therapy, enhancing the speed of diagnosing infectious diseases, and
advancing research and discovery of new drugs and vaccines. Since the
company caters to a niche market, it enjoys a monopoly over the segment
of cell analysis and flow cytometry.
According to BioSpectrum estimates, the revenue of the company for the
year 2010-11 excluding the diagnostics is `207 crore, marking a growth
of 15 percent over the revenue figure of `180 crore in the last fiscal.
In the next financial year, the company is expecting a 30 percent
growth. The company is a leader in the flow cytometry segment
commanding almost 85 percent of the market in India.
Recently, BD acquired Accuri Cytometers, a US company. The acquisition
expands BD’s presence into the emerging affordable personal flow
cytometer space. With this takeover of Accuri, which has a range of
products that are compact, easy-to-use, and affordable, the company is
looking at significant growth in 2011.
Besides the flow cytometry coupled with reagents, the company is also
growing with its business unit, Pharmingen. The company has introduced
more than 5,000 products addressing the needs of a broad spectrum of
biomedical researchers.
Commenting on future plan for the the company, Mr Sunit Trivedi,
director, BD Biosciences India says, “We certainly want to evolve. We
will be targeting the huge biotechnology education research market and
also focus on expanding our reach in training. The personalized flow
cytometry and higher education market offer a huge opportunity for
growth. We are trying to cater to this space with technology,
affordability and easy-to-use products.”
